The role of proB-type natriuretic peptide (proBNP) for the diagnosis of congestive heart failure (CHF) among patients presenting to the Emergency Department (ED) with dyspnea remains undefined. Accordingly, in the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, we are systematically assessing the value of proBNP (Elecsys ® proBNP Immunoassay, Roche Diagnostics Corporation) for the urgent evaluation of dyspneic patients with suspected acute CHF. Methods/Results: Enrollment for the PRIDE study has closed, and clinical follow up is to complete in October, 2003. The PRIDE study is a single-center, prospective, blinded trial of 600 patients, age >21 years, presenting with a complaint of dyspnea to an urban ED. Exclusion criteria include severe renal insufficiency (serum creatinine >2.5 mg/dl), ST segment depression or elevation on ECG, dyspnea following trauma, and >2 hours following urgent administration of intravenous loop diuretic. Following informed consent, information regarding demographics, past medical history, current medications, and presentation of each patient was gathered. A specimen of blood was collected for blinded proBNP measurement. At the end of standard clinical assessment (history, physical exam, ECG, chest x-ray), the treating ED physician provided a clinical estimate of the presence of CHF as the cause of dyspnea. The primary endpoint of the study will be a comparison of the predictive value of proBNP measurement versus clinical judgment for the presence of CHF at the time of clinical evaluation in the ED. Other endpoints will include correlation of proBNP levels with the diagnosis of CHF from presentation to 60 days of follow-up, as well as correlations with hospital length of stay.
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859-4 Nonterminal Pro B-Type Natriuretic Peptide in Patients With Chronic Heart Failure: Correlation With B-Type Natriuretic Peptide and Left Ventricular Structure and Function
Veselin Mitrovic, Inder Anand, Thorsten Dill, Michael Weber, Thomas Notter, Josef Schenk, Thomas F. Luescher, Christian W. Hamm, Kerckhoff Heart Center, Bad Nauheim, Germany
Background: Plasma levels of B-type natriuretic peptide (BNP) and non terminal pro BNP (NT-pro BNP) are increased in patients with systolic and diastolic left ventricular (LV) dysfunction and are important prognostic markers of chronic heart failure. The relation between NT-pro BNP, BNP, and LV structure and function in patients with chronic heart failure has not been studied. Methods: 523 patients (434 male, 89 female, mean age 60.7±11.4 years, LV ejection fraction 25±10.6%) in NYHA class II-IV, enrolled in the European part of the EARTH study, and 101 normal control subjects (61.5±7.4 years, ejection fraction 59.0±6.9%), were studied. LV endsystolic and enddiastolic volumes (ESV, EDV) were measured using magnetic resonance imaging, ejection fraction, stroke volume, cardiac output, and wall stress calculated. Plasma NT-pro BNP was measured using a newly developed sandwich enzyme-linked immunosorbent assay (ELISA) (Elecsys, Roche Diagnostics), and BNP measurement was performed by use of radio immunoassay (RIA). Results: NT-pro BNP [median, (25 th -75 th percentile)] was significantly increased as compared to the controls [942 (492-1977) versus 101 (61-163) pg/ml, p<0.0001]. Area under receiver operated curve was 0.96. At a cut-off point of 270 pg/ml, the specificity and sensitivity were 92% and 88% respectively. NT-pro BNP correlated significantly with BNP (r=0.79, p<0.001), LV ejection fraction (r=0.40, p<0.001), EDV (mean±standard deviation=256±94 ml, r=0.40, p<0.0001), ESV (197±91ml, r=0.24, p<0 .0001), and wall stress (63±18, r=0.32, p<0.005), but not with stroke volume or cardiac output. NT-pro BNP levels were significantly higher in patients who died (6 months, 21/523 patients), compared to those who survived (median NT-pro BNP, 3148 versus 1741 pg/ml, p<0.0001). NT-pro BNP above the median, and in the 3 rd and 4 th quartile were accociated with reduced survival (p<0.001). Conclusion: NT-pro BNP correlates well with BNP and LV volumes and is a significant predictor of mortality in patients with chronic heart failure.
ORAL CONTRIBUTIONS Background. The negative inotrope and upregulation of β 3 -adrenergic receptors (AR) in failing human and animal hearts suggest a direct and contributing role of cardiac β 3 -AR activation on heart failure (HF) progression. Therefore, we tested the hypothesis that chronic β 3 -AR blockade may limit or prevent the progression of HF.
Methods. Left ventricular (LV) and myocyte functional response and β 1 -and β 3 -AR expression were compared in 3 groups of rats (6 each) for a period of 4 months: 1) Isoproterenol (ISO)-treated, 4 months after receiving ISO (340 mg/kg, sq, for 2 days); 2) ISO/β 3 -ANT, one month after receiving ISO, L-748,337, a selective β 3 -AR antagonist (β 3 -ANT) (10 -7 M/kg/day by implanted osmotic mini pump) was initiated after the onset of HF and was given for 2 months; and 3) sham controls. 
